Daniel A. Salerno, MD, MS, Director of Critical Care Services in the Respiratory ICU at Temple University Hospital and Professor of Clinical Thoracic Medicine & Surgery at the Lewis Katz School of Medicine at Temple University, provided perspective to Medscape on new findings on brensocatib presented at the American College of Chest Physicians (CHEST) Annual Meeting in Chicago. The study examined the effect of brensocatib, which is newly approved by the U.S. Food and Drug Administration (FDA) for noncystic fibrosis bronchiectasis, on structural lung disease. Salerno was not involved in the study.
IMPORTANT: Labor & Delivery services have moved from Temple University Hospital–Main Campus (Broad & Ontario) to our new women & families hospital.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH